|
|
|
BioLargo Technology - Nature's Best Solution |
BioLargo offers patented technologies to deliver I2 (free iodine), for incorporation into products and delivery systems accross multiple industries. The company features technology, product enhancements and product designs that are environmentally sensitive, safe, and effective to help prevent disease and infection. | | | | | | | | * Nature's Best Disinfectant -Green Technology | | | | * Safe- GRAS | | | | * Most Potent & Broadest Spectrum | | | | * Flexible Delivery Methods & Precision Dosing | | | | * No Acquired Resistance Capability | | | | * Effective Odor Control | | | | | | CupriDyne™ | | By leveraging our suite of patented and patent-pending intellectual property, which we refer to as the BioLargo technology, our business strategy is to harness and deliver nature’s best disinfectant – iodine – in a safe, efficient, environmentally sensitive and cost-effective manner. Our BioLargo technology works by combining minerals with water from any source and delivering molecular iodine on demand, in controlled dosages, in order to balance efficacy of disinfectant performance with concerns about toxicity. When our BioLargo technology is incorporated in absorbent products, referred to as BI2O-SORB™ absorbents, third party testing has confirmed that the products also experience increased holding power and we believe that they may also experience increased absorption. Our BioLargo technology also includes know-how and trade secrets, which, together with our intellectual property, contribute to our expertise in product design, manufacturing, product claims, safety features and competitive positioning of products that feature our BioLargo technology. | | 
| | | | | | Our BioLargo technology creates a value-added proposition to existing products and can be used to create new products. Our BioLargo technology can be incorporated into absorbents, washes and sprays, and into various products and applications across multiple industry verticals. Our BioLargo technology has the potential to replace other disinfectants such as chlorines and bromines, which may be harmful to the environment. | | | | | |
| | The centerpiece of our BioLargo technology is CupriDyne™, a mineral and salt formulation that is the principal reactive agent we have focused on in our research and development, testing and patent protection to date and on which we will continue to devote substantial additional efforts. | | | | | | | | | Our business model is to license our BioLargo technology to others, rather than to manufacture our own products. Our current focus is to develop opportunities to license our BioLargo technology to others in various vertical markets rather than to manufacture our own products as evidenced by two recent strategic alliances with two leading corporations. (See the Company News) | | | | | | | | The Company is active in marketing its existing technology, developing new technology and related intellectual property and developing products for distribution through its licensing strategy. | | | | | | | | Strategic Alliance- Water Treatment Technology | | Isan® | | Through our strategic alliance with Ioteq IP Pty, Ltd., an Australian company, and its United States affiliate Ioteq, Inc., BioLargo represents and markets Ioteq’s iodine-based disinfection technology, Isan®, on an exclusive basis in the United States and on a non-exclusive basis in the rest of the world. | |  | | The Isan® water treatment system is an innovative, environmentally friendly, fully automated, cost effective disinfection solution for agriculture, horticulture, waste water, manufacturing, industrial and consumer applications. | |  | | The award winning and patented technology together with the patented form of pure iodine, which is both safe for the environment and easy to handle is revolutionizing industries where disinfection and water recycling have become critical. | |  | | The Isan water treatment system has been successfully commercialized and is in active operation with customers in Australia, New Zealand and currently in field trials in Japan.
| |  | |      | |  | | |
|
Last Updated ( Thursday, 13 November 2008 )
|
|
|